Quest Diagnostics Incorporated
0KSX.L
London Stock Exchange215.08
USD
+1.11
- -
Quest Diagnostics Incorporated
0KSX.L
(London Stock Exchange)
Recent
price
215.08
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Quest Diagnostics Incorporated (NYSE:DGX; LSE:0KSX) provides diagnostic information services through clinical laboratory testing to patients, physicians, hospitals, health insurers, and businesses across the United States, Canada, Puerto Rico, Mexico, and Brazil; offers routine clinical testing including blood-based tests for general health, infectious diseases, cardiometabolic risk factors, hormones, and inflammation markers, as well as advanced esoteric testing in oncology, genomics, gene-based diagnostics, anatomic pathology, minimal residual disease (MRD), Alzheimer's disease biomarkers such as blood-based AD-Detect, cytogenetics, flow cytometry, PCR, immunofluorescence, and next-generation sequencing; operates specialty labs like the Quest Cardiometabolic Center of Excellence at Cleveland HeartLab for cardiovascular, diabetes, kidney, and liver disease risk assessment; provides direct-to-consumer testing via questhealth.com and at-home collection kits encompassing over 85 health indicators without physician referral; delivers healthcare IT solutions including Quanum Lab Services Manager for test ordering and results, IntelliTest Manager, and lab analytics; and supports clinical trials, drug screening, life insurance assessments, and hospital co-lab services. Founded in 1967 as Metropolitan Pathology Laboratory (MetPath) in Manhattan, New York, by Dr. Paul A. Brown and now headquartered in Secaucus, New Jersey, the company employs nearly 50,000 people and serves one in three adult Americans and half of U.S. physicians and hospitals annually from more than 2,000 patient service centers. Recent developments include the 2024 completion of its approximately $1 billion (CAN $1.35 billion) acquisition of LifeLabs, Canada's leading diagnostics provider generating CAN $970 million in annual revenue, to expand North American operations and enhance access to advanced testing for an aging population; formation of a joint venture with Corewell Health in 2025 to deliver lab services including reference testing and analytics across 21 Michigan hospitals with projected annual revenue scaling to $1 billion; acquisition of select dialysis testing assets from Fresenius Medical Care to serve nearly 200,000 U.S. dialysis patients; consumer health partnerships with WHOOP for Advanced Labs integrating wearables with blood testing (over 350,000 waitlist signups) and Oura Health; collaboration with Epic to improve national lab testing experiences; FDA breakthrough designation for Haystack Oncology's MRD technology; publication of AD-Detect validation data; and raised 2025 revenue guidance to $10.8-$10.92 billion driven by LifeLabs integration, advanced diagnostics demand, and productivity gains amid strategic M&A investments of $500 million annually in physician outreach, hospital labs, and oncology.